Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
Per Selnes(Akershus University Hospital), Tormod Fladby(University of Oslo), Lisbeth Johnsen(Akershus University Hospital), Henrik Zetterberg(University of Wisconsin–Madison), Ramunė Grambaitė(Akershus University Hospital), Lars Rosengren(Sahlgrenska University Hospital), Vidar Stenset(University of Oslo), Kaj Blennow(Sahlgrenska University Hospital)
Cited by 52
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk
|Nature Genetics|2019|2.5k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k